Ocular Therapeutix Inc

Change company Symbol lookup

Select an option...

OCUL Ocular Therapeutix Inc

FCO Aberdeen Global Income Fund Inc.

DTEC ALPS Disruptive Technologies ETF

$RUIRETAILT Russell 1000 RGS Retail Total Return

BAC Bank of America Corp

MA Mastercard Inc

AAPL Apple Inc

AA Alcoa Corp

AMD Advanced Micro Devices Inc

PFE Pfizer Inc

Go

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.